JAE PAK: Open Payments
NPI 1740280551 · SNELLVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$534 in 25 payments from 10 companies in 2025. Trend: 2023 $453 · 2024 $312 · 2025 $534
Food & beverage: $534
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $119 |
| Teva Pharmaceuticals USA, Inc. | 4 | $80 |
| ACADIA Pharmaceuticals Inc | 3 | $79 |
| Vanda Pharmaceuticals Inc. | 4 | $79 |
| ABBVIE INC. | 3 | $50 |
| Eisai Inc. | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
Products named: INGREZZA, NUPLAZID, VRAYLAR, AUSTEDO XR, HETLIOZ, FANAPT, UZEDY, Leqembi.
Industry payments across GA — which companies pay providers there.
